newsfilter
← Latest News
GlobeNewswire·

Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference

  • Larimar Therapeutics (NASDAQ: LRMR) announced management participation in the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA from November 9-11, 2026.
  • The company's fireside chat is scheduled for Tuesday, November 10, 2026 at 10:00 AM EST with a webcast available at the provided link.
  • A replay of the fireside chat will be accessible for 30 days on Larimar's "Events and Presentations" webpage.
  • Larimar is a clinical-stage biotechnology company developing nomlabofusp as a potential treatment for Friedreich's ataxia.
  • The company utilizes its intracellular delivery platform to design fusion proteins targeting rare diseases characterized by deficiencies in intracellular bioactive compounds.
  • Investor inquiries can be directed to Joyce Allaire at LifeSci Advisors, while company inquiries should be sent to Chief Financial Officer Michael Celano.